SCHEMBL18367192

SCHEMBL18367192

Clc1nc(Cl)c2cnn(-c3ccccn3)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.44
DPP4 P27487 2/20 0.44
GSK3B P49841 1/20 0.40
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40
SLC2A1 P11166 1/20 0.39
SLC2A2 P11168 1/20 0.39
SLC2A3 P11169 1/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
AURKA O14965 1/20 0.39
FLT3 P36888 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MAPK14 Q16539 1/20 0.38
PTK2 Q05397 1/20 0.37
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
OXTR P30559 1/20 0.35
AVPR1A P37288 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30587545 1.00 CYP17A1 (0.44) CYP17A1DPP4GSK3BHPGDALDH1A1
SCHEMBL840321 0.81 GSK3B (0.52) CYP17A1DPP4GSK3BHPGDALDH1A1
SCHEMBL18367194 0.79 IRAK4 (0.42) CYP17A1DPP4GSK3BHPGDCYP1A2
SCHEMBL29387304 0.79 IRAK4 (0.42) CYP17A1DPP4GSK3BHPGDCYP1A2
SCHEMBL175236 0.78 ALDH1A1 (0.49) DPP4HPGDALDH1A1CYP1A2HSD17B10
SCHEMBL6344817 0.77 MAOA (0.46) CYP17A1DPP4GSK3BHPGDALDH1A1
SCHEMBL16981667 0.76 ALDH1A1 (0.47) GSK3BALDH1A1KMT2A
SCHEMBL30677333 0.73 GRM1 (0.53) CYP17A1GSK3BHPGDALDH1A1CYP1A2
SCHEMBL6341846 0.73 DPP4 (0.42) CYP17A1DPP4GSK3BHPGDALDH1A1
SCHEMBL6340222 0.72 CYP17A1 (0.39) CYP17A1DPP4GSK3BHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988459-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2021-04-27 US disclosed
EP-3760625-A1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES F. Hoffmann-La Roche AG (CH) 2021-01-06 EP disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10988459-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 CYP17A1 59/4885DPP4 3964/4885GSK3B 663/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 CYP17A1 59/4885DPP4 3964/4885GSK3B 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.